Montpellier

• Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip … Ended
  2022-500418-24-00 10 2020-01-17 Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
• REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer Ended
  2023-506248-18-00 7 2020-01-07 MET-altered non-small cell lung cancer (NSCLC)
• A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended
  2022-502886-71-00 5 2019-11-20 Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
• The Late Presenter Treatment Optimisation Study (LAPTOP) Ended
  2023-505167-36-00 5 2019-08-05 Patients who present late on during their acquisition of the HIV-1 (Hu
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended
  2023-508757-75-00 5 2017-09-18 Stage IV Non-Small Cell Lung Cancer (NSCLC)
• GASTRICHIP TRIAL. D2 resection and HIPEC (Hyperthermic IntraPeritoneal Chemoperfusion) in locally advanced gastric carcinoma. Ended
  2024-516358-23-00 5 2013-06-24 Gastric adenocarcinoma
• PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc … Ended
  2023-503807-27-00 4 Biliary tract carcinoma
• Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc … Ended
  2024-515533-15-00 4 Locally advanced cervical cancer

Showing 265–273 of 273 trials